Verastem PE Ratio 2011-2019 | VSTM

Current and historical p/e ratio for Verastem (VSTM) from 2011 to 2019. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Verastem PE ratio as of October 14, 2019 is 0.00.
Verastem PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2019-10-14 1.09 0.00
2019-06-30 1.51 $-1.75 0.00
2019-03-31 2.96 $-1.48 0.00
2018-12-31 3.36 $-1.37 0.00
2018-09-30 7.25 $-1.43 0.00
2018-06-30 6.88 $-1.75 0.00
2018-03-31 2.98 $-1.81 0.00
2017-12-31 3.07 $-1.75 0.00
2017-09-30 4.70 $-1.64 0.00
2017-06-30 2.18 $-1.24 0.00
2017-03-31 2.07 $-1.11 0.00
2016-12-31 1.12 $-0.98 0.00
2016-09-30 1.33 $-0.98 0.00
2016-06-30 1.30 $-1.19 0.00
2016-03-31 1.58 $-1.38 0.00
2015-12-31 1.86 $-1.62 0.00
2015-09-30 1.79 $-1.83 0.00
2015-06-30 7.54 $-1.93 0.00
2015-03-31 10.17 $-2.02 0.00
2014-12-31 9.14 $-2.07 0.00
2014-09-30 8.52 $-1.99 0.00
2014-06-30 9.06 $-1.94 0.00
2014-03-31 10.79 $-1.92 0.00
2013-12-31 11.40 $-1.85 0.00
2013-09-30 12.45 $-1.79 0.00
2013-06-30 13.88 $-1.83 0.00
2013-03-31 9.62 $-1.68 0.00
2012-12-31 8.79 $-1.71 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.081B $0.027B
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $120.420B 13.72
Gilead Sciences (GILD) United States $81.040B 9.95
CSL (CSLLY) Australia $75.707B 0.00
Celgene (CELG) United States $71.278B 11.03
Illumina (ILMN) United States $44.479B 52.26
Vertex Pharmaceuticals (VRTX) United States $44.315B 47.89
Biogen (BIIB) United States $41.170B 7.31
Regeneron Pharmaceuticals (REGN) United States $33.034B 14.99
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $22.255B 11.73
SINO PHARMACEUT (SBMFF) Hong Kong, SAR China $17.152B 0.00
Incyte (INCY) United States $16.371B 48.18
Seattle Genetics (SGEN) United States $13.358B 0.00
Genmab (GNMSF) Denmark $12.091B 67.82
BioMarin Pharmaceutical (BMRN) United States $12.089B 0.00
Exact Sciences (EXAS) United States $11.977B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.647B 51.72
Alnylam Pharmaceuticals (ALNY) United States $8.782B 0.00
Galapagos (GLPG) Belgium $8.522B 0.00
Bio-Techne Corp (TECH) United States $7.614B 52.60
Sarepta Therapeutics (SRPT) United States $6.206B 0.00
QIAGEN (QGEN) Netherlands $6.107B 20.06
ACADIA Pharmaceuticals (ACAD) United States $5.855B 0.00
Guardant Health (GH) United States $5.723B 0.00
BeiGene (BGNE) Cayman Islands $5.672B 0.00
Amarin (AMRN) Ireland $5.437B 0.00
Horizon Therapeutics Public (HZNP) Ireland $5.045B 12.82
Exelixis (EXEL) United States $5.004B 13.01
Bluebird Bio (BLUE) United States $4.871B 0.00
Moderna (MRNA) United States $4.641B 0.00
China Biologic Products (CBPO) China $4.534B 28.30
ARGENX SE-ADR (ARGX) Netherlands $4.267B 0.00
Medicines (MDCO) United States $4.127B 0.00
Ascendis Pharma (ASND) Denmark $4.007B 0.00
Repligen (RGEN) United States $3.992B 77.46
Spark Therapeutics (ONCE) United States $3.841B 0.00
Blueprint Medicines (BPMC) United States $3.618B 0.00
MorphoSys AG (MOR) Germany $3.371B 0.00
Mirati Therapeutics (MRTX) United States $3.023B 0.00
Reata Pharmaceuticals (RETA) United States $2.884B 0.00
Alkermes (ALKS) Ireland $2.831B 0.00
Immunomedics (IMMU) United States $2.720B 0.00
Emergent Biosolutions (EBS) United States $2.713B 40.76
Genomic Health (GHDX) United States $2.563B 48.07
Genmab (GMAB) Denmark $2.508B 0.00
MyoKardia (MYOK) United States $2.470B 0.00
Ultragenyx Pharmaceutical (RARE) United States $2.467B 0.00
Arena Pharmaceuticals (ARNA) United States $2.350B 5.05
Halozyme Therapeutics (HALO) United States $2.348B 0.00
RA PHARMCTL INC (RARX) United States $2.188B 0.00
Myriad Genetics (MYGN) United States $2.180B 22.88
Acceleron Pharma (XLRN) United States $2.080B 0.00
NeoGenomics (NEO) United States $2.049B 109.61
CRISPR Therapeutics AG (CRSP) Switzerland $2.020B 0.00
Cambrex (CBM) United States $2.008B 25.39
Ligand Pharmaceuticals (LGND) United States $2.006B 25.37
Amicus Therapeutics (FOLD) United States $2.000B 0.00
Intercept Pharmaceuticals (ICPT) United States $1.947B 0.00
Zai Lab (ZLAB) China $1.888B 0.00
Akcea Therapeutics (AKCA) United States $1.837B 0.00
UniQure (QURE) Netherlands $1.624B 0.00
Alder BioPharmaceuticals (ALDR) United States $1.582B 0.00
Insmed (INSM) United States $1.552B 0.00
Denali Therapeutics (DNLI) United States $1.474B 0.00
REGENXBIO (RGNX) United States $1.454B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.340B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $1.306B 0.00
Coherus BioSciences (CHRS) United States $1.294B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.113B 0.00
Innoviva (INVA) United States $1.079B 3.12
Zymeworks (ZYME) Canada $1.077B 0.00
Alector (ALEC) United States $1.034B 0.00
Dicerna Pharmaceuticals (DRNA) United States $1.015B 0.00
Editas Medicine (EDIT) United States $1.000B 0.00
Sangamo Therapeutics (SGMO) United States $0.949B 0.00
AnaptysBio (ANAB) United States $0.948B 0.00
Fate Therapeutics (FATE) United States $0.932B 0.00
Epizyme (EPZM) United States $0.913B 0.00
ANI Pharmaceuticals (ANIP) United States $0.866B 14.46
Athenex (ATNX) United States $0.845B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.805B 0.00
Anika Therapeutics (ANIK) United States $0.787B 27.86
Codexis (CDXS) United States $0.783B 0.00
Pharming Group (PHGUF) Netherlands $0.782B 0.00
Cara Therapeutics (CARA) United States $0.754B 0.00
Twist Bioscience (TWST) United States $0.738B 0.00
Zealand Pharma (ZEAL) Denmark $0.733B 8.23
Zealand Pharma (ZLDPF) Denmark $0.722B 0.00
Principia Biopharma (PRNB) United States $0.707B 365.63
ZIOPHARM Oncology Inc (ZIOP) United States $0.689B 0.00
WAVE Life Sciences (WVE) Singapore $0.688B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.677B 24.44
Cytokineticsorporated (CYTK) United States $0.656B 0.00
Vericel (VCEL) United States $0.638B 0.00
Mesoblast (MESO) Australia $0.617B 0.00
Arvinas (ARVN) United States $0.593B 0.00
Heska (HSKA) United States $0.569B 73.71
MiMedx (MDXG) United States $0.556B 0.00
Intellia Therapeutics (NTLA) United States $0.539B 0.00
Revance Therapeutics (RVNC) United States $0.537B 0.00
GENFIT S.A (GNFT) France $0.530B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.507B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.502B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.499B 0.00
PHARMA MAR SA (PHMMF) Spain $0.482B 0.00
Retrophin (RTRX) United States $0.480B 0.00
Sinovac Biotech (SVA) China $0.460B 0.00
UROGEN PHARMA (URGN) United States $0.455B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.445B 0.00
Intra-Cellular Therapies (ITCI) United States $0.428B 0.00
BioDelivery Sciences (BDSI) United States $0.425B 0.00
Cellectis S.A (CLLS) France $0.418B 0.00
DBV Technologies S.A (DBVT) France $0.407B 0.00
Stemline Therapeutics (STML) United States $0.385B 0.00
Arcus Biosciences (RCUS) United States $0.376B 0.00
AMAG Pharmaceuticals (AMAG) United States $0.375B 0.00
Merus (MRUS) Netherlands $0.374B 0.00
Syros Pharmaceuticals (SYRS) United States $0.373B 0.00
Precision BioSciences (DTIL) United States $0.366B 0.00
Agenus (AGEN) United States $0.361B 0.00
Bellus Health (BLU) Canada $0.361B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.351B 0.00
Adverum Biotechnologies (ADVM) United States $0.341B 0.00
Kadmon Holdings (KDMN) United States $0.337B 0.00
AC Immune SA (ACIU) Switzerland $0.329B 24.35
CytomX Therapeutics (CTMX) United States $0.323B 0.00
Prothena (PRTA) Ireland $0.310B 0.00
Gritstone Oncology (GRTS) United States $0.308B 0.00
Avid Bioservices (CDMO) United States $0.299B 0.00
Geron (GERN) United States $0.288B 0.00
Cellular Biomedicine (CBMG) United States $0.287B 0.00
Theratechnologies (THTX) Canada $0.285B 0.00
Protagonist Therapeutics (PTGX) United States $0.284B 0.00
Starpharma Holdings (SPHRY) Australia $0.279B 0.00
Scholar Rock Holding (SRRK) United States $0.279B 0.00
Puma Biotechnology (PBYI) United States $0.277B 0.00
PDL BioPharma (PDLI) United States $0.267B 6.88
Biofrontera AG (BFRA) Germany $0.265B 395.33
Dynavax Technologies (DVAX) United States $0.256B 0.00
Kindred Biosciences (KIN) United States $0.255B 0.00
MannKind (MNKD) United States $0.243B 0.00
Prometic Life Sciences (PFSCF) Canada $0.235B 0.00
ADMA Biologics Inc (ADMA) United States $0.235B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.225B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.224B 0.00
Sutro Biopharma (STRO) United States $0.219B 0.00
Inovio Pharmaceuticals (INO) United States $0.216B 0.00
Seres Therapeutics (MCRB) United States $0.215B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.215B 0.00
Albireo Pharma (ALBO) United States $0.215B 0.00
Compugen (CGEN) Israel $0.214B 0.00
OSMOTICA PHARM (OSMT) United States $0.213B 0.00
Sorrento Therapeutics (SRNE) United States $0.210B 0.00
Athersys (ATHX) United States $0.209B 0.00
Spero Therapeutics (SPRO) United States $0.206B 0.00
Kamada (KMDA) Israel $0.205B 7.85
POXEL SA FRANCE (PXXLF) France $0.204B 0.00
Exicure (XCUR) United States $0.192B 0.00
ChromaDex (CDXC) United States $0.188B 0.00
Clovis Oncology (CLVS) United States $0.179B 0.00
Dyadic (DYAI) United States $0.176B 0.00
Nicox SA (NICXF) France $0.175B 0.00
Enzo Biochem (ENZ) United States $0.174B 0.00
Bicycle Therapeutics (BCYC) United Kingdom $0.171B 0.00
Affimed (AFMD) Germany $0.171B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.168B 0.00
Cue Biopharma (CUE) United States $0.167B 0.00
Senesco Technologies (ELOX) United States $0.165B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.162B 0.00
XOMA (XOMA) United States $0.156B 0.00
Alcobra (ARCT) United States $0.153B 0.00
Five Prime Therapeutics (FPRX) United States $0.152B 0.00
Arsanis (XFOR) United States $0.146B 0.00
Cerecor (CERC) United States $0.138B 0.00
Northwest Biotherapeutics (NWBO) United States $0.137B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.133B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.132B 0.00
NantKwest (NK) United States $0.123B 0.00
PHASEBIO PHARMA (PHAS) United States $0.119B 0.00
Acorda Therapeutics (ACOR) United States $0.116B 0.00
SESEN BIO, INC (SESN) United States $0.114B 0.00
Menlo Therapeutics (MNLO) United States $0.114B 0.00
Windtree Therapeutics (WINT) United States $0.113B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.111B 0.00
Abeona Therapeutics (ABEO) United States $0.110B 0.00
Novavax (NVAX) United States $0.109B 0.00
Strongbridge Biopharma (SBBP) United States $0.109B 4.47
Paratek Pharmaceuticals (PRTK) United States $0.105B 0.00
Aptinyx (APTX) United States $0.104B 0.00
Emmaus Life Sciences (EMMA) United States $0.100B 0.00
OvaScience (MLND) United States $0.097B 0.00
Celyad SA (CYAD) Belgium $0.093B 0.00
VBI Vaccines (VBIV) United States $0.093B 0.00
Trevena (TRVN) United States $0.091B 0.00
Vaccinex (VCNX) United States $0.089B 0.00
Fortress Biotech (FBIO) United States $0.086B 0.00
Adocia (ADOCY) France $0.086B 0.00
Aduro Biotech (ADRO) United States $0.082B 0.00
Aquinox Pharmaceuticals (NLTX) Canada $0.081B 0.00
VTv Therapeutics (VTVT) United States $0.081B 0.00
Antibe Therapeutics (ATBPF) Canada $0.079B 0.00
ARAVIVE, INC (ARAV) United States $0.077B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.076B 0.00
Liquidia Technologies (LQDA) United States $0.076B 0.00
Checkpoint Therapeutics (CKPT) United States $0.075B 0.00
Mersana Therapeutics (MRSN) United States $0.072B 0.00
Idera Pharmaceuticals (IDRA) United States $0.072B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.071B 0.00
Curis (CRIS) United States $0.069B 0.00
Synlogic (SYBX) United States $0.069B 0.00
Selecta Biosciences (SELB) United States $0.065B 0.00
Prima BioMed (IMMP) Australia $0.064B 0.00
Catalyst Biosciences (CBIO) United States $0.063B 0.00
Orgenesis (ORGS) United States $0.059B 21.59
Catabasis Pharmaceuticals (CATB) United States $0.058B 0.00
Pluristem Therapeutics (PSTI) Israel $0.057B 0.00
Applied Genetic Technologies (AGTC) United States $0.056B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.055B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.053B 0.00
Arbutus Biopharma (ABUS) Canada $0.053B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.052B 0.00
AquaBounty Technologies (AQB) United States $0.051B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.051B 0.00
AIT Therapeutics (XAIR) United States $0.048B 0.00
Vascular Biogenics (VBLT) Israel $0.046B 0.00
VistaGen Therapeutics (VTGN) United States $0.045B 0.00
Stellar Biotechnologies (EDSA) Canada $0.044B 0.00
NewLink Genetics (NLNK) United States $0.044B 0.00
Unum Therapeutics (UMRX) United States $0.043B 0.00
Evogene (EVGN) Israel $0.042B 0.00
VIVUS (VVUS) United States $0.042B 0.00
Ophthotech (ISEE) United States $0.042B 0.00
INNOVATE BIOPHARMACEUTICALS, INC (INNT) United States $0.041B 0.00
Proteostasis Therapeutics (PTI) United States $0.040B 0.00
Oncobiologics (OTLK) United States $0.038B 0.00
Organovo Holdings (ONVO) United States $0.036B 0.00
Celsion (CLSN) United States $0.036B 0.00
Celldex Therapeutics (CLDX) United States $0.033B 0.00
Entera Bio (ENTX) Israel $0.030B 0.00
Clearside Biomedical (CLSD) United States $0.029B 0.00
Fibrocell Science Inc (FCSC) United States $0.029B 9.90
Alimera Sciences (ALIM) United States $0.028B 0.00
Aptevo Therapeutics (APVO) United States $0.026B 0.00
Signal Genetics (MGEN) United States $0.025B 0.00
BioCardia (BCDA) United States $0.024B 0.00
DiaMedica Therapeutics (DMAC) United States $0.022B 0.00
Caladrius Biosciences (CLBS) United States $0.022B 0.00
Aytu Bioscience (AYTU) United States $0.021B 0.00
Novogen (KZIA) Australia $0.020B 0.00
Aerpio Pharmaceuticals (ARPO) United States $0.020B 0.00
Apricus Biosciences (SEEL) United States $0.020B 0.00
AEterna Zentaris (AEZS) United States $0.018B 0.00
Soligenix (SNGX) United States $0.018B 0.00
CollPlant Holdings (CLGN) Israel $0.016B 0.00
Prana Biotechnology (ATHE) Australia $0.015B 0.00
Pulmatrix (PULM) United States $0.014B 0.00
TOCAGEN INC (TOCA) United States $0.014B 0.00
MYOS RENS Technology (MYOS) United States $0.013B 0.00
Cleveland BioLabs (CBLI) United States $0.011B 0.00
IMMURON (IMRN) Australia $0.011B 0.00
TRACON Pharmaceuticals (TCON) United States $0.010B 0.00
Benitec Biopharma (BNTC) Australia $0.008B 0.00
Genetic Technologies (GENE) Australia $0.008B 0.00
Titan Pharmaceuticals (TTNP) United States $0.007B 0.00
Cyclacel Pharmaceuticals (CYCC) United States $0.006B 0.00
TrovaGene (TROV) United States $0.006B 0.00
Bionano Genomics (BNGO) United States $0.006B 0.00
Advaxis (ADXS) United States $0.006B 0.00
Neuralstem (CUR) United States $0.002B 0.00